期刊文献+

SH2-ODC/AZ1腺病毒的构建及对BCR-ABL蛋白的降解效应

Construction of adenovirus SH2-ODC/AZ1 and its degradation effect on BCR-ABL
下载PDF
导出
摘要 目的构建重组腺病毒Ad-SH2-ODC和Ad-AZ1,检测共表达SH2-ODC和AZ1蛋白对BCR-ABL癌蛋白的降解效应。方法PCR扩增src同源结构域2(src homology 2,SH2)、鸟氨酸脱羧酶(ornithine decarboxylase,ODC)及抗酶蛋白1(antizyme 1,AZ1)基因,构建携带SH2-ODC(SO)或AZ1基因的p Ad Track-CMV腺病毒穿梭质粒,经双酶切和测序鉴定后与腺病毒骨架质粒p Ad Easy-1同源重组,获得重组腺病毒质粒。后者经PacⅠ酶切鉴定后,在人胚肾细胞系AD293中包装、扩增,获得重组腺病毒;腺病毒Ad-SO和Ad-AZ1共感染人白血病细胞系K562,western blot检测目的蛋白的表达。结果双酶切和测序证实,腺病毒穿梭质粒构建正确;PacⅠ酶切结果显示,重组腺病毒质粒构建成功;western blot证实目的蛋白在K562细胞中表达正确,共表达SO和AZ1可以降低BCR-ABL蛋白水平。结论成功构建了Ad-SO和Ad-AZ1重组腺病毒,共表达SO和AZ1可以降解K562细胞中的BCR-ABL蛋白。 Objective To construct the recombination adenoviruses Ad-SH2-ODC and Ad-AZ1, and explore the degradation effect of SH2-ODC and AZl co-expression system on BCR-ABL oncoprotein. Methods The fragments of SH2 (src homology 2) , ODC( orni- thine decarboxylase) and AZ1 (antizyme 1 ) gene were amplified by PCR and cloned into shuttle vector pAdTrack-CMV. The shuttle plasmids were digested by Pme I and homologously recombined with backbone plasmid AdEasy-1. After identification by Pac I diges- tion, adenoviruses were packaged and amplified in human embryonic kidney AD293 cells. The expressions of fusion protein and BCR- ABL in human leukocyte K562 cells co-infected with adenoviruses Ad-SO and Ad-AZl were detected by western blot. Results The shuttle plasmids of adenovirus were confirmed to be correctly contructed by double digestion and gene sequencing. The fusion proteins expressed by recombination adenovirus plasmids were verified by Pac I digestion. The constructed adenoviruses were expressed in K562 cells. BCR-ABL protein level decreased in SO/AZ1 co-expressed K562 cells. Conclusion The adenoviruses Ad-SO and Ad- AZ1 were constructed successfully. The SO/AZl co-express system may degrade BCR-ABL protein in K562 cells.
出处 《临床检验杂志》 CAS CSCD 2015年第4期301-305,共5页 Chinese Journal of Clinical Laboratory Science
基金 教育部博士点基金资助项目(20125503110005)
关键词 BCR-ABL 抗酶蛋白1 SH2结构域 鸟氨酸脱羧酶 BCR-ABL antizyme 1 SH2 domain ornithine decarboxylase
  • 相关文献

参考文献15

  • 1Quints-Cardama A, Cortes J. Molecular biology of bcr abll -positive chronic myeloid leukemia [J]. Blood, 2009,113 ( 8 ) : 1619 -1630.
  • 2Balabanov S, Braig M, Brtimmendorf TH. Current aspects in resist- ance against tyrosine kinase inhibitors in chronic myelogenous leuke- mia[J]. Drug Discov Today Techno1,2014,11:89-99.
  • 3Kahana C. Regulation of cellular polyamine levels and cellular prolif- eration by antizyme and antizyme inhibitor [J]. Essays Biochem, 2009, 46:47-61.
  • 4Liu YC, Liu YL, Su JY, et al. Critical factors governing the differ- ence in antizyme-binding affinities between human ornithine decar- boxylase and antizyme inhibitor [J]. PLoS One, 2011, 6(4) :e19253.
  • 5Chu S, Li L, Singh H, et cd. BCR-tyrosine 177 plays an essemial role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia [J]. Caneer Res, 2007,67 ( 14 ) :7045-7053.
  • 6史静,彭智,罗红伟,曹唯希,陶崑,李亚娟,王海霞,冯文莉.重组腺病毒Ad5-hSH2-EGFP及其突变体的构建与鉴定[J].中国生物制品学杂志,2011,24(5):507-512. 被引量:10
  • 7Luo J, Deng ZL, Luo X, et al. A protocol for rapid generation of re- combinant adenoviruses using the AdEasy system [J]. Nat Protoc, 2007,2(5) :1236-1247.
  • 8Cea M, Cagnetta A, Nencioni A, et al. New insights into biology of chronic myeloid leukemia: implications in therapy[J]. Curr Cancer Drug Targets,2013,13(7) :711-723.
  • 9Pegg AE. Regulation of ornithine decarboxylase [J]. J Biol Chem, 2006,281 (21) :14529-14532.
  • 10Peng Z,Yuan Y, Li YJ,et al. Targeting BCR tyrosine177 site with novel SH2-DED causes selective leukemia cell death in vitro and in vivo[J]. Int J Biochem Cell Biol, 2012,44(6) :861-868.

二级参考文献13

  • 1Krause,DS,Van,Etten,RA,黄艳.癌症治疗的靶点——酪氨酸激酶[J].中国处方药,2005(10):33-36. 被引量:45
  • 2Druker BJ. Translation of the Philadelphia chromosome into therapyfor CML[J]. Blood, 2008, 112(13) : 4808-4817.
  • 3Quintas-Cardama A, Kantarjian H,Cortes J. Flying under the radar :the new wave of BCR-ABL inhibitors [ J ]. Nat Rev Drug Discov,2007,6(10) : 834-848.
  • 4Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myeloge-nous leukemia [ J ]. N Engl J Med, 2007,357(3 ) : 258-265.
  • 5Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL inducedoncogenesis is mediated by direct interaction with the SH2 domain ofthe GRB-2 adaptor protein[ J]. Cell, 1993 ,75( 1 ) : 175-185.
  • 6Puil L, Liu J, Gish G, et al. Bcr-Abl oncoproteins binddirectly toactivators of the Ras signalling pathway[ J]. EMBO J,1994,13(4):764-773.
  • 7Chu S, Li L, Singh H,et al. BCR-tyrosine 177 plays an essentialrole in Ras and Akt activation and in human hematopoietic progenitortransformation in chronic myelogenous leukemia [ J ]. Cancer Res,2007,67(14) :7045-7053.
  • 8KischkelFC, Lawrence DA, Chuntharapai A, et al. FADD/MORT1and caspase-8 are recruited to TRAIL receptors 1 and 2 and are es-sential for apoptosis mediated by TRAIL receptor 2 [ J] . Immunity,2000, 12(6) :599-609.
  • 9PengZ,Yuan Y,Li YJ, et al. Targeting BCR tyrosinel77 site withnovel SH2-DED causes selective leukemia cell death in vitro and invivo[J]. Int J Biochem Cell Biol, 2012,44(6) :861-868.
  • 10Uno K,Inukai T, Kayagaki N, et al. TNF-related apoptosis-indu-cing ligand (TRAIL) frequently induces apoptosis in Philadelphiachromosome-positive leukemia cells [ J ]. Blood, 2003,101 ( 9 ):3658-3667.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部